Schedule 13G ownership disclosure
KINIKSA PHARMACEUTICALS INTL
Common Stock · CUSIP: G52694109
Event date: 2025-09-30
- Filing-level shares
- 3,063,135
- Percent of class
- 7.04%
- The Vanguard Group
Shares: 3,063,135 · Class: 7.04%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000102909-25-000265
- Form type
- SCHEDULE 13G/A
- Filer
- Kiniksa Pharmaceuticals International, plc
- CIK
- CIK 1730430
- Filed
- Oct 31, 2025
- Reporting period
- Sep 30, 2025
- Description
- Schedule 13G beneficial ownership